Cyclosporine mitigates graft coronary artery disease in murine cardiac allografts: Description and validation of a novel fully allogeneic model

Relatively high-dose CsA mitigated parenchymal rejection and GCAD of the mouse cardiac allografts. In addition, a valuable mouse model mimicking the clinical course of GCAD was achieved with CsA treatment of 20 mg/kg/day for 30 days.